Wang SS, Davenport AJ, Iliopoulos M, Hughes-Parry HE, Watson KA, Arcucci V, Maulazzani M, Eisenstat DD, Hansford JR, Cross RS and Jenkins MR. 2023. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Accepted. In Press.
Prasad K, Cross RS and Jenkins MR. 2023. Synthetic biology, genetic circuits and machine learning: A new age of cancer therapy. Mol Oncol. Accepted. In Press. March 10 2023.
Abbott RC, Iliopoulos M, Watson KA, Arcucci V, Go M, Hughes-Perry HE, Smith P, Call MJ, Cross RS and Jenkins MR. 2023. Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. Clin Trans Immunol. PMID: 36890859.
Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen JV, Trenker R, Jenkins MR, Call MJ, Call ME & Fleishman SJ. 2022. Do novo designed receptor transmembrane domains enhance CART cell cytotoxicity and attenuate cytokine release. E Life. May 4;11:e75660. PMID: 35506657.
Moujalled D, Southon A, Saleh E, Brinkmann K, Ke K, Iliopoulos, Cross R, Jenkins MR, Nhu D, Wang Z, Shi M, Kluck R, Lessene G, Grabow S Bush A and Strasser A. 2022. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death and Diff. Mar 24. PMID:35332309.
Luke J, Dalach P, Tuer L, Svarirayan R, Ferdinand, McGaughran J, Kowal E, Massey L, Garvey G, Dawkins H, Jenkins M, Paradies Y, Pearson G, Stutterd CA, Baynam G and Kelaher M. 2022. Investigating disparity in access to Australian clinical genetic health services for Aboriginal and Torres Strait Islander people. Nature Communications. 2022. PMID: 36002448.
Abbott RC, Hughes-Parry HE and Jenkins MR (Senior/Corr). 2022. To GO OR NOT to GO? Biological logic gating engineered T cells. Journal for ImmunoTherapy of Cancer. Apr;10(4):e004185. PMID: 35379738.
Jenkins MR et al. Challenges and opportunities in 2021. 2021. Nature Cancer. Dec;2(12):1278-1283. PMID: 35121916.
Wang SS, et al and Jenkins MR (Senior/Corr). 2021. A novel peptide-MHC targeted Chimeric Antigen Receptor T cell forms a T cell-like immune synapse. Biomedicines. Dec10;9(12):1875. PMID: 34944696.
Verdon DJ & Jenkins MR (Senior/Corr). 2021. Identification and targeting of mutant peptide neoantigens in cancer immunotherapy. Cancers. Aug 23;13(16):4245. PMID: 34439399.
Abbott RC et al, Jenkins MR (Senior/Corr). 2021. Novel High-Affinity EGFRvIII-specific Chimeric Antigen Receptor T cells effectively eliminate Human Glioblastoma. Clin Trans Immunol.
Abbott RC, Cross RS and Jenkins MR (Senior/Corr). 2020. Finding the keys to the CAR: Identifying novel target antigens for T Cell redirection Immunotherapies. Int J Mol Sci.
Hughes-Parry HE, Cross RS and Jenkins MR (Senior/Corr). 2020. The evolving protein engineering in the design of Chimeric Antigen Receptor T cells. Int J Mol Sci.
Sant S, Jenkins MR, et al Kedzierska K. 2019. Clinical and Translational Immunology. 2019.
Wang SS, Bandopadhayay P and Jenkins MR (Senior/Corr). Towards Immunotherapy for Paediatric Brain Tumours. 2019. Trends in Immunology. IF=15. PMID: 31229353.
Davenport AJ, Cross RS, Watson KA, Liao Y. Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ and Jenkins MR. Chimeric antigen receptor T cells forms nonclassical and potent immune synapses driving rapid cytotoxicity. Proceedings National Academy of Sciences. 2018. PMID: 29440406
Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I and Trapani JA. et al. Failed CTL/NK cell killing and cytokine hypersecretion and directly linked through prolonged synapse time. Journal of Experimental Medicine. 2015. PMID: 25732304
*Davenport A, *Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, Trapani JA, Kershaw MH, Darcy PK and Neeson PJ. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunology Research. 2015 May;3(5):483-94. PMID: 25711536 *Joint 1st
Jenkins MR, Stinchcombe JC, Au-Yeung BB, Asano Y, Ritter AT, Weiss A and Griffiths GM.et al. Distinct structural and catalytic roles for Zap70 in formation of the immunological synapse. eLife. 2014. Jan 1;3:e01310. PMID: 24596147
*Lopez JA and *Jenkins MR, Rudd-Schmidt JA, Brennan AJ, Danne JC, Mannering SI, Trapani JA and Voskoboinik I. Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse. Journal of Immunology. 2013. PMID: 23885110 *Joint 1st
Jenkins MR, Tsun A, Stinchcombe JC and Griffiths GM. The strength of T cell receptor signal controls the polarization of cytotoxicity machinery to the Immunological synapse. Immunity. 2009. *This article was highlighted in Science. PMID: 19833087
Jenkins MR, La Gruta NL, Doherty PC, Trapani JA, Turner SJ and Waterhouse NJ. Visualizing CTL Activity for Different CD8+ Effector T Cells Supports the Idea that Lower TCR/Epitope Avidity May be Advantageous for target cell killing. Cell Death and Differentiation. 2009. 1-6. PMID: 19136939
Jenkins MR, Trapani JA, Doherty PC and Turner SJ. Granzyme K expressing CTL protect against influenza virus in granzyme AB-/- mice. Viral Immunology. 2008. 21:3. 341-346. PMID: 18788942
Jenkins MR, Mintern J, La Gruta NL, Kedzierska K, Doherty PC and Turner SJ. Cell cycle-related acquisition of cytotoxic mediators defines the progressive differentiation to effector status for virus-specific CD8+ T cells. Journal of Immunology. 2008.181:3818-3822. PMID: 18768835
Jenkins MR, Kedzierska K, Doherty PC and Turner SJ. Heterogeneity of effector phenotype for acute phase and memory Influenza A virus-specific CTL. Journal of Immunology. 2007:179:64-70. PMID: 17579022